Publications by authors named "John L Lederer"

Article Synopsis
  • The study aimed to evaluate how effective the SpaceOAR hydrogel is in reducing radiation proctitis when combined with prostate brachytherapy in a group of 731 patients.
  • Among patients using the hydrogel, the incidence of radiation proctitis was significantly lower (4.1%) compared to those not using it (12.2%), with specific rates showing even greater reductions in different treatment scenarios.
  • The findings suggest that SOAR not only reduces the occurrence of radiation proctitis but also highlights the need for more research to understand inflammation patterns observed during treatment.
View Article and Find Full Text PDF

Objectives: The aim of the present study was to report on our early experience with hydrogel spacer (SpaceOAR) placement in combination with iodine-125 low-dose-rate brachytherapy for prostate cancer.

Methods: From April 2018, SpaceOAR hydrogel spacer was placed in 100 consecutive patients undergoing iodine-125 low-dose-rate brachytherapy. Complications and the status of the placement were evaluated.

View Article and Find Full Text PDF

Background: Our aim was to report clinical and biochemical outcomes of transperineal interstitial permanent prostate brachytherapy in the treatment of Japanese patients with clinically organ-confined prostate cancer in Hawaii.

Methods: Ninety-five Japanese patients underwent transperineal interstitial permanent prostate brachytherapy using either iodine-125 or palladium-103 for clinical T1c-T2b N0 M0 prostate cancer. These procedures were carried out between December 1998 and December 2002 at The Queen's Medical Center in Honolulu, Hawaii.

View Article and Find Full Text PDF

Purpose: We described the temporarily increase phenomenon in prostate-specific antigen level (PSA bounce) after transperineal interstitial permanent prostate brachytherapy (TIPPB) for localized prostate cancer.

Materials And Methods: From December 1998 to May 2003, 500 consecutive patients with localized prostate cancer were treated with TIPPB using iodine-125 or palladium-103. We examined 200 patients who have more than 2-year PSA follow-up.

View Article and Find Full Text PDF